• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rapid resolution of recalcitrant basal cell carcinoma of the ear with topical tirbanibulin.

作者信息

Moore Angela, Hurley Kara, Moore Stephen A

机构信息

Arlington Center for Dermatology, Arlington, Texas.

Arlington Research Center, Arlington, Texas.

出版信息

JAAD Case Rep. 2022 Aug 10;28:11-13. doi: 10.1016/j.jdcr.2022.07.035. eCollection 2022 Oct.

DOI:10.1016/j.jdcr.2022.07.035
PMID:36090193
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9450055/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/285f/9450055/9908d2e342c5/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/285f/9450055/0800587c1bdd/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/285f/9450055/4bbf842102d7/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/285f/9450055/e957683bc74c/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/285f/9450055/9908d2e342c5/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/285f/9450055/0800587c1bdd/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/285f/9450055/4bbf842102d7/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/285f/9450055/e957683bc74c/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/285f/9450055/9908d2e342c5/gr4.jpg

相似文献

1
Rapid resolution of recalcitrant basal cell carcinoma of the ear with topical tirbanibulin.外用替巴尼布林可快速消退耳部难治性基底细胞癌
JAAD Case Rep. 2022 Aug 10;28:11-13. doi: 10.1016/j.jdcr.2022.07.035. eCollection 2022 Oct.
2
Real-world experience with histological confirmation of clinical response of squamous cell carcinoma to topical tirbanibulin.鳞状细胞癌对局部用替巴尼布林临床反应的组织学确认的真实世界经验。
JAAD Case Rep. 2023 Jul 14;40:141-144. doi: 10.1016/j.jdcr.2023.07.005. eCollection 2023 Oct.
3
A systematic review of patient-reported outcome instruments of nonmelanoma skin cancer in the dermatologic population.皮肤科人群中非黑色素瘤皮肤癌患者报告结局测评工具的系统评价
J Am Acad Dermatol. 2013 Aug;69(2):e59-67. doi: 10.1016/j.jaad.2012.09.017. Epub 2012 Oct 24.
4
Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.咪喹莫特或氟尿嘧啶局部治疗基底细胞癌和鳞状细胞癌：一项系统评价
Arch Dermatol. 2009 Dec;145(12):1431-8. doi: 10.1001/archdermatol.2009.291.
5
Evaluation of the effect of surgical treatment on quality of life with the Dermatology Life Quality Index in patients with facial nonmelanoma skin cancer.采用皮肤病生活质量指数评估手术治疗对面部非黑素瘤皮肤癌患者生活质量的影响。
Dermatol Ther. 2020 Nov;33(6):e14094. doi: 10.1111/dth.14094. Epub 2020 Aug 14.
6
Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis.有非黑色素瘤皮肤癌病史的患者发生后续非黑色素瘤皮肤癌的风险：文献综述与荟萃分析
Arch Dermatol. 2000 Dec;136(12):1524-30. doi: 10.1001/archderm.136.12.1524.
7
Topical tirbanibulin resolves recalcitrant condyloma acuminata: Retrospective case series.外用替瑞布林治疗顽固性尖锐湿疣：回顾性病例系列研究
JAAD Case Rep. 2023 Apr 26;37:58-60. doi: 10.1016/j.jdcr.2023.04.011. eCollection 2023 Jul.
8
Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group.电离辐射治疗后基底细胞癌和鳞状细胞癌的风险。皮肤癌预防研究小组。
J Natl Cancer Inst. 1996 Dec 18;88(24):1848-53. doi: 10.1093/jnci/88.24.1848.
9
Treatment of cutaneous tumors with topical 5% imiquimod cream.局部应用 5%咪喹莫特乳膏治疗皮肤肿瘤。
Clinics (Sao Paulo). 2009;64(10):961-6. doi: 10.1590/S1807-59322009001000005.
10
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.三期临床试验研究替比嘧啶软膏治疗光化性角化病。
N Engl J Med. 2021 Feb 11;384(6):512-520. doi: 10.1056/NEJMoa2024040.

引用本文的文献

1
Real-world experience with tirbanibulin 1% ointment for the treatment of nonmelanoma skin cancer following cryotherapy: A pilot study.1%替拉替尼软膏用于冷冻治疗后非黑色素瘤皮肤癌治疗的真实世界经验：一项试点研究。
JAAD Int. 2024 Nov 29;18:168-170. doi: 10.1016/j.jdin.2024.11.005. eCollection 2025 Feb.
2
Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment.光化性角化病的局部药物治疗：聚焦于1%替拉替林软膏
Dermatol Pract Concept. 2024 Jul 1;14(3 S1):e2024145S. doi: 10.5826/dpc.1403S1a145S.
3
Topical and Intralesional Immunotherapy for the Management of Basal Cell Carcinoma.

本文引用的文献

1
Topical tirbanibulin eradication of periungual squamous cell carcinoma.外用替巴尼布林根除甲周鳞状细胞癌。
JAAD Case Rep. 2021 Jun 26;14:101-103. doi: 10.1016/j.jdcr.2021.06.013. eCollection 2021 Aug.
2
Guidelines of care for the management of actinic keratosis.光化性角化病治疗管理指南。
J Am Acad Dermatol. 2021 Oct;85(4):e209-e233. doi: 10.1016/j.jaad.2021.02.082. Epub 2021 Apr 2.
3
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.三期临床试验研究替比嘧啶软膏治疗光化性角化病。
用于基底细胞癌治疗的局部和瘤内免疫疗法
Cancers (Basel). 2024 Jun 4;16(11):2135. doi: 10.3390/cancers16112135.
4
Synthesis and evaluation of tirbanibulin derivatives: a detailed exploration of the structure-activity relationship for anticancer activity.替尔泊肽衍生物的合成与评价：抗癌活性构效关系的详细探索
RSC Adv. 2023 Dec 6;13(50):35583-35591. doi: 10.1039/d3ra06790d. eCollection 2023 Nov 30.
5
Real-world experience with histological confirmation of clinical response of squamous cell carcinoma to topical tirbanibulin.鳞状细胞癌对局部用替巴尼布林临床反应的组织学确认的真实世界经验。
JAAD Case Rep. 2023 Jul 14;40:141-144. doi: 10.1016/j.jdcr.2023.07.005. eCollection 2023 Oct.
N Engl J Med. 2021 Feb 11;384(6):512-520. doi: 10.1056/NEJMoa2024040.
4
Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma.原发性纤毛丧失驱动基底细胞癌耐药中 Hedgehog 通路向 Ras/MAPK 通路的转变。
J Invest Dermatol. 2019 Jul;139(7):1439-1448. doi: 10.1016/j.jid.2018.11.035. Epub 2019 Jan 29.
5
Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations.基底细胞癌：流行病学；发病机制；临床和组织学亚型；以及疾病相关性。
J Am Acad Dermatol. 2019 Feb;80(2):303-317. doi: 10.1016/j.jaad.2018.03.060. Epub 2018 May 18.
6
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).新型Src 信号和微管聚合双重作用机制抑制剂（KX2-391 和 KX2-361）的发现。
J Med Chem. 2018 Jun 14;61(11):4704-4719. doi: 10.1021/acs.jmedchem.8b00164. Epub 2018 Apr 17.
7
Elevated c-Src and c-Yes expression in malignant skin cancers.恶性皮肤癌中 c-Src 和 c-Yes 的表达升高。
J Exp Clin Cancer Res. 2010 Aug 27;29(1):116. doi: 10.1186/1756-9966-29-116.